Tips and traps analyzing pediatric PK data

Paediatric Anaesthesia

Volumn 21, Issue 3, 2011, Pages 222-237

  Anderson, Brian J ^a   Holford, Nick H G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

allometry; models; pediatric; pharmacokinetics; pharmacology

Indexed keywords

CLONIDINE; DIAZEPAM; DIGOXIN; MORPHINE; PARACETAMOL; PROPOFOL; VANCOMYCIN;

AGE; BODY SIZE; DISEASE COURSE; DRUG HALF LIFE; DUCHENNE MUSCULAR DYSTROPHY; GLOMERULUS FILTRATION RATE; HUMAN; MATURATION; OBESITY; PAIN; PERINATAL PERIOD; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TONSILLECTOMY;

ADULT; AGING; ALGORITHMS; ANESTHESIA; ANESTHETICS; BODY COMPOSITION; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; MODELS, STATISTICAL; OBESITY; PHARMACOKINETICS; RESEARCH DESIGN;

EID: 79951637480     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2011.03536.x     Document Type: Review

References (110)

1. Holford NH,. The target concentration approach to clinical drug development. Clin Pharmacokinet 1995; 29: 287-291.
2. Holford N,. Dosing in children. Clin Pharmacol Ther 2010; 87: 367-370.
3. Stephenson T,. How children's responses to drugs differ from adults. Br J Clin Pharmacol 2005; 59: 670-673. (Pubitemid 40835499)
4. Lerman J,. Pharmacology of inhalational anaesthetics in infants and children. Paediatr Anaesth 1992; 2: 191-203.
5. LeDez KM, Lerman J,. The minimum alveolar concentration (MAC) of isoflurane in preterm neonates. Anesthesiology 1987; 67: 301-307. (Pubitemid 18077407)
6. Lerman J, Robinson S, Willis MM, et al. Anesthetic requirements for halothane in young children 0-1 month and 1-6 months of age. Anesthesiology 1983; 59: 421-424. (Pubitemid 14227515)
7. Tod M, Jullien V, Pons G,. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008; 47: 231-243. (Pubitemid 351367434)
8. Anderson BJ, Holford NH,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332. (Pubitemid 351738156)
9. Anderson BJ, Holford NH,. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
10. Savage VM, Deeds EJ, Fontana W,. Sizing up allometric scaling theory. PLoS Comput Biol 2008; 4: e1000171.
11. Holford NHG,. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-332. (Pubitemid 26177179)
12. Su F, Nicolson SC, Gastonguay MR, et al. Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg 2010; 110: 1383-1392.
13. Knibbe CA, Krekels EH, van den Anker JN, et al. Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 2009; 48: 371-385.
14. Sumpter AL, Holford NHG,. Predicting weight using postmenstrual age-neonates to adults. Paediatr Anaesth 2011; 21: 309-315.
15. Beal SL, Boeckmann AJ, Sheiner LB,; NONMEM Project Group. NONMEM Users Guides, Version V edn. San Francisco: University of California at San Francisco, 1999.
16. Engle WA,. Age terminology during the perinatal period. Pediatrics 2004; 114: 1362-1364. (Pubitemid 41647702)
17. Hill AV,. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol 1910; 40 (Suppl): iv-vii.
18. Richards FJ,. A flexible growth function for empirical use. J Exp Bot 1959; 10: 290-301.
19. Anand KJ, Anderson BJ, Holford NH, et al. Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br J Anaesth 2008; 101: 680-689.
20. Potts AL, Warman GR, Anderson BJ,. Dexmedetomidine disposition in children: a population analysis. Paediatr Anaesth 2008; 18: 722-730. (Pubitemid 352000581)
21. Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
22. Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009; 85: 56-63.
23. Allegaert K, Peeters MY, Verbesselt R, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth 2007; 99: 864-870. (Pubitemid 351773375)
24. Peeters MY, Allegaert K, Blusse van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269-275.
25. Menson EN, Walker AS, Sharland M, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332: 1183-1187.
26. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 1997; 86: 10-23. (Pubitemid 27043998)
27. Rigby-Jones AE, Priston MJ, Sneyd JR, et al. Remifentanil-midazolam sedation for paediatric patients receiving mechanical ventilation after cardiac surgery. Br J Anaesth 2007; 99: 252-261. (Pubitemid 47249397)
28. Lynn A, Nespeca MK, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86: 958-963. (Pubitemid 28198858)
29. Pokela ML, Olkkola KT, Seppala T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20: 26-34. (Pubitemid 24169492)
30. Peters JW, Anderson BJ, Simons SH, et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006; 45: 705-714. (Pubitemid 43990571)
31. Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75-84. (Pubitemid 44902880)
32. Xie HG, Cao YJ, Gauda EB, et al. Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. J Clin Pharmacol 2010; Epub May 19: PMID 20484620.
33. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008; 101: 523-530.
34. Efron B, Tibshirani R,. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat Sci 1986; 1: 54-77.
35. Dutta S, Matsumoto Y, Ebling WF,. Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies? J Pharm Sci 1996; 85: 232-239.
36. Cheymol G,. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39: 215-231.
37. Han PY, Duffull SB, Kirkpatrick CM, et al. Dosing in obesity: a simple solution to a big problem. Clin Pharmacol Ther 2007; 82: 505-508. (Pubitemid 47622534)
38. Abernethy DR, Greenblatt DJ,. Drug disposition in obese humans. An update. Clin Pharmacokinet 1986; 11: 199-213. (Pubitemid 16079739)
39. Ewy GA, Groves BM, Ball MF, et al. Digoxin metabolism in obesity. Circulation 1971; 44: 810-814.
40. Abernethy DR, Greenblatt DJ, Divoll M, et al. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983; 101: 873-880. (Pubitemid 13100682)
41. Abernethy DR, Greenblatt DJ, Divoll M, et al. Prolonged accumulation of diazepam in obesity. J Clin Pharmacol 1983; 23: 369-376. (Pubitemid 13009590)
42. Casati A, Putzu M,. Anesthesia in the obese patient: pharmacokinetic considerations. J Clin Anesth 2005; 17: 134-145. (Pubitemid 40462234)
43. Green B, Duffull S,. Caution when lean body weight is used as a size descriptor for obese subjects. Clin Pharmacol Ther 2002; 72: 743-744. (Pubitemid 36021015)
44. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-1065. (Pubitemid 41356391)
45. Duffull SB, Dooley MJ, Green B, et al. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet 2004; 43: 1167-1178. (Pubitemid 40013182)
46. Bouillon T, Shafer SL,. Does size matter? Anesthesiology 1998; 89: 557-560. (Pubitemid 28423950)
47. FDA. Guidance for industry: general considerations for pediatric pharmacokinetic studies for drugs and biological products. 1998.
48. Anderson BJ, Woollard GA, Holford NH,. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol 2001; 57: 559-569.
49. Hughes MA, Glass PS, Jacobs JR,. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76: 334-341.
50. McFarlan CS, Anderson BJ, Short TG,. The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr Anaesth 1999; 9: 209-216. (Pubitemid 29220117)
51. Potts AL, Anderson BJ, Holford NH, et al. Dexmedetomidine hemodynamics in children after cardiac surgery. Paediatr Anaesth 2010; 20: 425-433.
52. Jamei M, Dickinson GL, Rostami-Hodjegan A,. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 2009; 24: 53-75.
53. Johnson TN,. The problems in scaling adult drug doses to children. Arch Dis Child 2008; 93: 207-211. (Pubitemid 352025489)
54. Johnson TN, Rostami-Hodjegan A, Tucker GT,. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956. (Pubitemid 44299829)
55. Edginton AN, Schmitt W, Voith B, et al. A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 2006; 45: 683-704. (Pubitemid 43990570)
56. Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4: 1143-1152.
57. de Simone G, Devereux RB, Daniels SR, et al. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997; 95: 1837-1843. (Pubitemid 27164401)
58. Laer S, Barrett JS, Meibohm B,. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol 2009; 49: 889-904.
59. Hu C, Zhang J, Zhou H,. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat 2009; Epub Dec 29: PMID 20041468.
60. Mouksassi MS, Marier JF, Cyran J, et al. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther 2009; 86: 667-671.
61. Friis-Hansen B,. The extracellular fluid volume in infants and children. Acta Paediatr 1954; 43: 444-458.
62. Fisher DM, O'Keeffe C, Stanski DR, et al. Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 1982; 57: 203-208. (Pubitemid 12057041)
63. Paradisis M, Jiang X, McLachlan AJ, et al. Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Arch Dis Child Fetal Neonatal Ed 2007; 92: F204-F209. (Pubitemid 46698118)
64. van der Marel C, Anderson BJ, van Lingen RA, et al. Paracetamol and metabolite pharmacokinetics in infants. Eur J Clin Pharmacol 2003: 59: 243-251. (Pubitemid 36995133)
65. Penson RT, Joel SP, Clark S, et al. Limited phase I study of morphine-3-glucuronide. J Pharm Sci 2001; 90: 1810-1816. (Pubitemid 33062602)
66. Lotsch J, Weiss M, Kobal G, et al. Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. Clin Pharmacol Ther 1998; 63: 629-639. (Pubitemid 28327890)
67. Bouwmeester NJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004; 92: 208-217. (Pubitemid 38159658)
68. Herd B, Wynne H, Wright P, et al. The effect of age on glucuronidation and sulphation of paracetamol by human liver fractions. Br J Clin Pharmacol 1991; 32: 768-770.
69. Campanero MA, Calahorra B, Valle M, et al. Enantiomeric separation of tramadol and its active metabolite in human plasma by chiral high-performance liquid chromatography: application to pharmacokinetic studies. Chirality 1999; 11: 272-279. (Pubitemid 29198019)
70. Ahsman MJ, Hanekamp M, Wildschut ED, et al. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010; 49: 407-419.
71. Wittwer E, Kern SE,. Role of morphine's metabolites in analgesia: concepts and controversies. AAPS J 2006; 8: E348-E352. (Pubitemid 43840593)
72. Romberg R, Olofsen E, Sarton E, et al. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology 2004; 100: 120-133. (Pubitemid 38031663)
73. van Dorp EL, Romberg R, Sarton E, et al. Morphine-6-glucuronide: morphine's successor for postoperative pain relief? Anesth Analg 2006; 102: 1789-1797. (Pubitemid 43799857)
74. Osborne PB, Chieng B, Christie MJ,. Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus. Br J Pharmacol 2000; 131: 1422-1428.
75. Murthy BR, Pollack GM, Brouwer KL,. Contribution of morphine-6- glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 2002; 42: 569-576. (Pubitemid 34438556)
76. Osborne R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-138.
77. Thompson PI, Joel SP, John L, et al. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40: 145-152.
78. Gong QL, Hedner J, Bjorkman R, et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249-255.
79. Smith MT, Watt JA, Cramond T,. Morphine-3-glucuronide - a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579-585. (Pubitemid 20282122)
80. Jung D, Mroszczak E, Bynum L,. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 1988; 35: 423-425.
81. Mandema JW, Stanski DR,. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60: 619-635. (Pubitemid 27025909)
82. Mroszczak EJ, Lee FW, Combs D, et al. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos 1987; 15: 618-626. (Pubitemid 18004616)
83. Jallad NS, Garg DC, Martinez JJ, et al. Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. J Clin Pharmacol 1990; 30: 76-81. (Pubitemid 20072729)
84. Byon W, Fletcher CV, Brundage RC,. Impact of censoring data below an arbitrary quantification limit on structural model misspecification. J Pharmacokinet Pharmacodyn 2008; 35: 101-116. (Pubitemid 351420764)
85. Jonsson EN, Sheiner LB,. More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther 2002; 72: 603-614. (Pubitemid 36021000)
86. Hu C, Sale ME,. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30: 83-103. (Pubitemid 36571070)
87. Bergstrand M, Karlsson MO,. Handling data below the limit of quantification in mixed effect models. AAPS J 2009; 11: 371-380.
88. Yang S, Roger J,. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data. Pharm Stat 2009; 9: 313-330.
89. Ahn JE, Karlsson MO, Dunne A, et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401-421.
90. Chan PL, Holford NH,. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol 2001; 41: 625-659. (Pubitemid 32385901)
91. Anderson BJ, Holford NH, Woollard GA, et al. Perioperative pharmacodynamics of acetaminophen analgesia in children. Anesthesiology 1999; 90: 411-421. (Pubitemid 29071508)
92. Lavy JA,. Post-tonsillectomy pain: the difference between younger and older patients. Int J Pediatr Otorhinolaryngol 1997; 42: 11-15. (Pubitemid 27481262)
93. Murthy P, Laing MR,. Dissection tonsillectomy: pattern of post-operative pain, medication and resumption of normal activity. J Laryngol Otol 1998; 112: 41-44. (Pubitemid 28067484)
94. Toma AG, Blanshard J, Eynon Lewis N, et al. Post-tonsillectomy pain: the first ten days. J Laryngol Otol 1995; 109: 963-964.
95. Brown RD, Kearns GL, Wilson JT,. Integrated pharmacokinetic- pharmacodynamic model for acetaminophen, ibuprofen, and placebo antipyresis in children. J Pharmacokinet Biopharm 1998; 26: 559-579. (Pubitemid 29157783)
96. Anderson BJ, Brown TC,. Congenital myotonic dystrophy in children-a review of ten years' experience. Anaesth Intensive Care 1989; 17: 320-324. (Pubitemid 19203107)
97. Holford NHG,. The visual predictive check-superiority to standard diagnostic (Rorschach) Plots PAGE. Pamplona:, 2005.
98. Karlsson MO, Savic RM,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20. (Pubitemid 46944205)
99. Yano Y, Beal SL, Sheiner LB,. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-192.
100. Duffull SB, Kirkpatrick CM, Green B, et al. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat 2005; 15: 53-73. (Pubitemid 40130000)
101. Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 2008; 35: 185-202.
102. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction corrected visual predictive checks. ACOP: American College on Pharmacometrics, 2009:,.
103. Standing JF, Hammer GB, Sam WJ, et al. Pharmacokinetic-pharmacodynamic modeling of the hypotensive effect of remifentanil in infants undergoing cranioplasty. Paediatr Anaesth 2010; 20: 7-18.
104. Comets E, Brendel K, Mentre F,. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
105. Potts AL, Anderson BJ, Warman GR, et al. Dexmedetomidine pharmacokinetics in pediatric intensive care-a pooled analysis. Paediatr Anaesth 2009; 19: 1119-1129.
106. Dallimore D, Anderson BJ, Short TG, et al. Ketamine anesthesia in children-exploring infusion regimens. Paediatr Anaesth 2008; 18: 708-714. (Pubitemid 352000584)
107. Engelhardt T, McCheyne AJ, Morton N, et al. Clinical adaptation of a pharmacokinetic model of Propofol plasma concentrations in children. Paediatr Anaesth 2008; 18: 235-239. (Pubitemid 351159907)
108. Allegaert K, de Hoon J, Verbesselt R, et al. Maturational pharmacokinetics of single intravenous bolus of propofol. Paediatr Anaesth 2007; 17: 1028-1034. (Pubitemid 47481127)
109. Chalkiadis GA, Anderson BJ,. Age and size are the major covariates for prediction of levobupivacaine clearance in children. Pediatr Anesth 2006; 16: 275-282.
110. Gobburu JV, Holford NHG,. Vz, the terminal phase volume: time for its terminal phase? J Biopharm Stat 2011; 11: 373-375.